FDA Clears Tysabri For Limited Clinical Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients who had previously been receiving the multiple sclerosis therapy are now eligible to participate in Biogen Idec/Elan’s pending safety extension study.